External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme

BACKGROUND AND AIMS: Trastuzumab provides clinical benefit for advanced and early breast cancer patients whose tumours over‐express or have gene amplification of the HER2 oncogene. The UK National External Quality Assessment Scheme (NEQAS) for immunohistochemical testing was established to assess an...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Bartlett, John M S, Ibrahim, Merdol, Jasani, Bharat, Morgan, John M, Ellis, Ian, Kay, Elaine, Magee, Hilary, Barnett, Sarah, Miller, Keith
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Group 2007
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC1995794/
https://ncbi.nlm.nih.gov/pubmed/16963466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jcp.2006.040840
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg